Latest News

BlueRock Therapeutics, Start-up based on UHN Technology, Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership

August 17, 2017/in  

Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicinebluerock

Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations

TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announces the expansion of the company’s presence in...

Read More

We’re hiring: Licensing and Commercialization Associate

August 8, 2017/in   

Join the TDC Team at UHN!  

Please apply online.

Job Posting #809308
Position: Licensing and Commercialization Associate
Site: MaRS – Heritage Building
Department: Technology Development & Commercialization (TDC) 
Reports to: Team Lead, Licensing and Commercialization
Salary Range: Commensurate with experience and consistent with UHN Compensation Policy
Status: Temporary Full-Time, 1 year contract

University Health Network (UHN) is Canada’s largest research hospital and has a proud history of innovative research and important discoveries. Researchers at UHN are focused on...

Read More

UHN Start-up Acumyn dramatically reduces the time spent on quality assurance

July 28, 2017/in  

acumyn 2

Source: Canadian Healthcare Technology, VOL.22, NO.5 JUNE/JULY 2017

Dr. Christopher Paige named UHN Inventor of the Year

June 15, 2017/in   

Longtime UHN researcher Dr. Christopher Paige has been named Inventor of the Year for his work in immune-oncology, a promising therapeutic approach based on the premise that a patient's own immune system has powerful cancer-fighting capabilities if correctly activated and targeted.

Dr. Paige, who for close to two decades as UHN's Vice-President of Research, and later as Executive Vice- President (EVP) of Science and Research, championed commercialization as a strategy to transform discoveries into practical medical products to benefit patients, received the award at yesterday's UHN Annual General Meeting in the MaRS Auditorium.

Each year,...

Read More

Princess Margaret Cancer Centre Innovation Acceleration Fund Announces 1st Round of 2017 Awards to Researchers to Develop Early Stage Technologies

June 15, 2017/in   

June 2nd, 2017 TORONTO, ON – The Princess Margaret Cancer Centre’s Innovation Accelerator Fund (IAF) Leadership Board has announced three new awardees in its first funding round of 2017.  The IAF was established by The Princess Margaret Cancer Foundation in collaboration with University Health Network’s Technology Development and Commercialization Office in January 2016 to help investigators at the Princess Margaret Cancer Centre accelerate their early-stage research discoveries towards commercialization.  The fund provides a maximum of $250,000 per proposal, helping to take novel technologies from bench-to-bedside. The three winning projects of the latest call include:

Generation of inhibitors targeting V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS...

Read More

UHN Spin-Off Thornhill Medical’s MOVES® SLC™ Portable Emergency Life Support System Receives 510K Clearance From The US FDA

June 8, 2017/in  

TORONTO, June 8, 2017 /PRNewswire/ – Thornhill Medical, has received notification from the US FDA that the MOVES® SLC™ Portable Emergency Life Support System has received 510K clearance. This approval expands the capabilities of the current MOVES® SLC™ system, including Pediatric Settings, Expanded Patient Monitoring Modes, New Ventilator Modes, and a Remote Monitoring and Control Interface.

“The US FDA 510K clearance represents a significant milestone in the development of our emergency medical device portfolio. The MOVES® SLC™ has been tested in extreme conditions of temperature, altitude, shock, vibration, EMC, sand, dust, and rain. It has also been fully evaluated by the US Army Aeromedical Research Laboratory at Ft. Rucker (USAARL). As such, the MOVES® SLC™ is the ideal solution for...

Read More

The Ministry of Health and Long Term Care of Ontario launches a home sleep test demonstration project with BresoDx®

May 25, 2017/in  

News Release

The Ministry of Health and Long Term Care of Ontario launches a home sleep test demonstration project with BresoDx®,  

Toronto, Canada, May 16, 2017 – BresoDx®, developed by BresoTec and a technology developed at Toronto Rehabilitation Institute of the University Health Network (UHN), has been selected by the Ministry of Health and Long-Term Care (MOHLTC) for use in a home-based sleep apnea demonstration project with sleep clinics across Ontario. For the first time in the province, patients and sleep physicians will have the option to diagnose sleep apnea in the home.


UHN-based MolecuLight i:X™ gets Worldwide Distribution

May 5, 2017/in   

Smith & Nephew signs exclusive worldwide distribution agreement for the revolutionary MolecuLight i:X™ imaging device

NEWS PROVIDED BY Smith & Nephew plc 

03 May, 2017, 09:00 BST

Smith & Nephew logo.LONDON, May 3, 2017 /PRNewswire/ – Smith & Nephew plc (LSE: SN, NYSE: SNN), a global leader in medical technology, today announces it has signed a worldwide distribution agreement with MolecuLight®, Inc., a developer of innovative...

Read More

UHN Start-ups in the news: Improving lives around the world!

April 3, 2017/in   


Both UHN start-ups MolecuLight I:X and BresoTec Inc., were recognized for their global impact as diagnostic tools in the Toronto Star. Read the details of how UHN’s cutting-edge technology is changing lives around the world HERE!


We’re hiring! Licensing and Commercialization Associate

March 30, 2017/in  

Licensing and Commercialization Associate - Toronto, Ontario

Please apply on-line at:

Job Posting #800940

Position: Licensing and Commercialization Associate
Site: MaRS – Heritage Building
Department: Technology Development & Commercialization (TDC) 
Reports to: Team Lead, Licensing and Commercialization
Salary Range: Commensurate with experience and consistent with UHN...

Read More

Two UHN oncologists and two cancer scientists have received the 2017 Canadian Cancer Society Awards for Excellence announced today!

March 8, 2017/in  

We are incredibly proud to announce that two cancer program oncologists and two cancer scientists have received the 2017 Canadian Cancer Society Awards for Excellence announced today. These Awards recognize individuals who have made, and are making, valuable contributions to cancer research and cancer control in Canada. Recipients are leaders in their fields who exemplify excellence in science and outstanding service to the scientific community.Read more at:

We salute Drs. Brian O’Sullivan, Philippe Bedard, Mathieu Lupien and Daniel De Carvalho as exemplary clinicians/scientists, mentors and role models, and terrific ambassadors for the cancer program and UHN.  ...

Read More

UHN-developed experimental gene therapy for Fabry disease is tested in first human patient; AVROBIO, Inc. to further develop therapy worldwide

March 6, 2017/in  

University Health Network (UHN) in Toronto, ON has commenced Phase 1 testing of its novel cell and gene therapy for Fabry disease, pioneered within the lab of Dr. Jeffrey Medin (now at the Medical College of Wisconsin). AVROBIO, Inc. is the exclusive licensee for this therapy, and is further developing it worldwide.  A leader in lentiviral-based gene therapies, AVROBIO is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. Headquartered in Cambridge, MA, AVROBIO also has offices in Toronto, ON.  For additional information, visit

Learn more about this breakthrough milestone in Global News’ coverage below!


Read More

Princess Margaret Cancer Centre champions Canadian excellence in health research on Roche global cancer research network

February 14, 2017/in 

Partnership positions Princess Margaret Cancer Centre to provide Canadian perspective on a Network of 21 academic centres from...

Read More

UHN licenses Artificial Intelligence technology for automated radiation therapy treatment planning to RaySearch

February 2, 2017/in  /by 


Techna and UHN’s Technology Development and Commercialization office are pleased to announce that UHN has exclusively licensed a new artificial intelligence (AI) technology for automated treatment planning to RaySearch Laboratories AB, a global leader in radiation therapy treatment planning systems, for incorporation into the RayStation® platform which is currently used in over 2,600 clinics in more than 65...

Read More

TDC Medical Device Commercialization Internship available for May 2017 Start

January 30, 2017/in   


Have an interest in commercialization? Experience with Medical Devices and market analysis? A scientific background? Join the TDC team as our TDC Medical Device Commercialization Intern starting this May, 2017.


Job Title:  Medical Device Commercialization Intern (6 months full-time, May-Oct)
Company Name:  University Health Network, Office of Technology Development & Commercialization
Location:   MaRS Discovery District, 101 College Street
Interview Date...
Read More

TDC in the News!

January 24, 2017/in  

New Stem Cell Company Launched

Ontario Premier Kathleen Wynne speaking at a news conference, held in the MaRS Discovery District in Toronto, announcing the creation of BlueRock Therapeutics.

Announced on Jan 11, 2017

BlueRock Therapeutics, co-founded by UHN researchers, receives historic investment.

German drug-maker Bayer AG and American venture capital firm Versant Ventures are investing US$225 million to create a new biotechnology company, BlueRock Therapeutics, which will develop stem cell-based treatments for a...

Read More

Announcing the next call of the Princess Margaret Cancer Centre Innovation Acceleration Fund! Deadline January 31st, 2017

January 12, 2017/in  

Attention Princess Margaret Researchers: Translate your novel research into clinical care with $250,000!

Seeking, but not limited to, validated targets requiring hit compound screens.
ALL at PMCC including PIs, RAs & Grad Students are encouraged to apply.
Deadline for submission is 5pm, January 31, 2017.

Eligible Princess Margaret employees can find additional details and application forms on TDC’s Intranet site here.

For questions and queries please contact Bharti Ranavaya, IAF Manager & Business Development and...

Read More

Princess Margaret Cancer Foundation meets Billion Dollar Challenge!

January 11, 2017/in  

The Princess Margaret Cancer Foundation is thrilled to announce the successful achievement of the Billion Dollar Challenge, in partnership with the Princess Margaret Cancer Centre at University Health Network.

Read more about this incredible achievement here:

Prostate Cancer Researchers Discover Genetic Fingerprint to Identify How and When Disease Initially Spreads


January 10, 2017/in  

Dr. Robert Bristow, clinician-scientist at Princess Margaret Cancer Centre, says the findings explain why up to 30 per cent of men with potentially curable localized prostate cancer develop aggressive disease that spreads. (Video: UHN)

​​​(TORONTO, Canada – Jan. 9, 2017) –  Canadian prostate cancer researchers have discovered the genetic fingerprint that explains why up to 30 per cent of men with potentially curable localized prostate cancer develop aggressive disease that spreads following radiotherapy or surgery.

The findings, published online today in Nature, could help clinicians personalize effective, targeted therapies from the moment of diagnosis, says co-principal investigator Robert Bristow, clinician-scientist at the Princess...

Read More

Join us for a workshop series on strategic trends in the Medical Devices industry at Rotman School of Management!

January 3, 2017/in   

Presented by Rotman Centre for Health Sector Strategy in partnership with the University Health Network Office of Technology Development & Commercialization.

The goal of this series is to address the key strategic trends to aid those working within the industry as well as entrepreneurs or new entrants to the medical devices arena. Topics and examples will focus on Canadian and global companies. Participation will involve focused pre-readings, together with active engagement in discussions during the sessions.

Audience Mix: This medical devices workshop series are non-credit seminars open to industry executives as well as graduate business and medical students. The Rotman Centre for Health Sector Strategy will issue a certificate of completion for attendees who participate...

Read More